Clinical Trial Update: A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment). [Phase 2]

View source ↗

Summary

This Phase 2 pharmacokinetic study evaluated how etravirine (TMC125) plus tenofovir/emtricitabine, with or without boosted darunavir/ritonavir, behaves in the b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Intelence (Etravirine)
• Norvir (ritonavir)
• PREZISTA (darunavir)
• TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)

Snippet

Sponsor: Tibotec, Inc | Conditions: HIV-1 Infection | Phase 2 | Status: COMPLETED | Results posted: 2010-04-12